Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Average Recommendation of “Moderate Buy” from Analysts

Posted by Brenda Bartman on May 21st, 2026

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) have earned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $27.5556.

Several research analysts recently issued reports on CAI shares. Weiss Ratings raised shares of Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Jefferies Financial Group assumed coverage on Caris Life Sciences in a report on Monday, April 13th. They issued a “buy” rating and a $28.00 target price for the company. New Street Research began coverage on shares of Caris Life Sciences in a report on Friday, May 8th. They set a “market perform” rating for the company. BTIG Research reduced their price objective on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Caris Life Sciences in a report on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price target for the company.

Get Our Latest Analysis on Caris Life Sciences

Insider Buying and Selling at Caris Life Sciences

In other Caris Life Sciences news, Director Jeff L. Vacirca acquired 31,050 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $16.15 per share, for a total transaction of $501,457.50. Following the completion of the acquisition, the director directly owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. This represents a 166.75% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Caris Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC boosted its stake in Caris Life Sciences by 99,900.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after acquiring an additional 999 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Caris Life Sciences by 839.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after purchasing an additional 1,469 shares during the period. Olistico Wealth LLC bought a new position in shares of Caris Life Sciences during the fourth quarter worth about $31,000. Fifth Third Bancorp bought a new position in shares of Caris Life Sciences during the 1st quarter worth approximately $31,000. Finally, Sterling Capital Management LLC grew its position in Caris Life Sciences by 128.3% in the first quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after purchasing an additional 1,083 shares in the last quarter.

Caris Life Sciences Price Performance

NASDAQ CAI opened at $15.70 on Thursday. The stock has a fifty day moving average of $18.44. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. Caris Life Sciences has a 52-week low of $14.19 and a 52-week high of $42.50. The firm has a market cap of $4.44 billion and a price-to-earnings ratio of -2.06.

Caris Life Sciences (NASDAQ:CAI – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. Caris Life Sciences had a return on equity of 98.28% and a net margin of 3.75%.The business had revenue of $292.89 million for the quarter, compared to analysts’ expectations of $281.00 million. During the same period in the previous year, the business posted ($1.73) earnings per share. Caris Life Sciences’s quarterly revenue was up 125.4% on a year-over-year basis. As a group, sell-side analysts expect that Caris Life Sciences will post 0.1 earnings per share for the current fiscal year.

About Caris Life Sciences

(Get Free Report)

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.

Analyst Recommendations for Caris Life Sciences (NASDAQ:CAI)

Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.